Oncotelic Therapeutics, Inc.
No SEC Form 4 filings for $OTLC in the last 30 days.
See all $OTLC insider activity →Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 3, 2026, by and between ONCOTELIC THERAPEUTICS, INC. , a Delaware corporation, with headquarters located at 29397 Agoura Road Suite 107
Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (this “ Agreement ”) is made and entered into as of July 10, 2026 (the “ Grant Date ”) by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “ Company
Trieu Vuong (CHAIRMAN AND CEO) purchased 240,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.04 on 2026-07-01.
Over the past 7 days, alphai's AI scored 1 news story mentioning OTLC (Oncotelic Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent OTLC coverage spans insider activity and corporate actions.
The filing discloses a new convertible debt and equity issuance arrangement, which can pressure dilution expectations and change near-term financing risk.
The filing signals management compensation is contingent on achieving a national exchange uplisting, which can affect perceived execution risk and governance optics.
Insider open-market purchase by the CEO/Chairman can be read as confidence, but it is not a fundamental catalyst like guidance, trial data, or financing.
The filing discloses a new convertible debt/equity-linked financing that can dilute common holders upon conversion and may pressure near-term sentiment.
Insider open-market buying by the CEO/Chairman can be a modest sentiment tailwind, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions OTLC with an AI model for sentiment and relevance, and aggregates insider trades from Oncotelic Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 3, 2026, by and between ONCOTELIC THERAPEUTICS, INC. , a Delaware corporation, with headquarters located at 29397 Agoura Road Suite 107
4 min readOncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (this “ Agreement ”) is made and entered into as of July 10, 2026 (the “ Grant Date ”) by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “ Company
3 min readTrieu Vuong (CHAIRMAN AND CEO) purchased 240,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.04 on 2026-07-01.
2 min readOncotelic Therapeutics, Inc. (OTLC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 23, 2026, by and between ONCOTELIC THERAPEUTICS, INC. , a Delaware corporation, with headquarters located at 29397 Agoura Road Suite 107,
4 min readTrieu Vuong (CHAIRMAN AND CEO) purchased 255,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.04 across 3 trades over 2026-06-22 to 2026-06-24.
2 min readShah Amit B. (CFO) purchased 20,000 shares of Oncotelic Therapeutics, Inc. (OTLC) at $0.05 on 2026-06-22.
2 min readTrieu Vuong (CHAIRMAN AND CEO) purchased 335,759 shares of Oncotelic Therapeutics, Inc. (OTLC) at an average of $0.04 ($0.04–$0.04) across 2 trades over 2026-06-15 to 2026-06-17.
2 min read